Oncopeptides CSO released from custody
March 10, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, has been informed that the company’s Chief Scientific Officer Jakob Lindberg was today released from custody. This, after being arrested on Wednesday March 8th, allegedly for unauthorized disclosure of inside information in October 2021.
“We have fully cooperated with the Swedish Economic Crime Authority since this has come to our attention and will continue doing so moving forward. In the meantime, the company will continue to focus on bringing an important therapy to patients with multiple myeloma in the EU”, says Monica Shaw, CEO Oncopeptides.
Jakob Lindberg assumed his position as Chief Scientific Officer (CSO), January 4. He was the Company’s CEO from 2011, until June 2020, as well as from November 2021 until January 2023. During July 2020 until November2021 he was CSO.
Currently, the Company has no further comments regarding this event, and specific questions concerning the preliminary investigation, can be directed to the Swedish Economic Crime Authority.
For more information, please contact:
Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ.)
Cell phone: + 46 70 262 96 28
Oncopeptides is a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform, PDC, to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US. On December 7, 2022, the FDA recommended that the Company voluntarily withdraw the US marketing authorization for Pepaxto.
Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com.